A Study Of Mircera In Patients With Kidney Disease Who Are Not On Dialysis

Mircera In Patients With CKD Stages III-IV Not On Dialysis: Observational, Non-interventional Cohort Study

This open-label, non-randomized, retrospective-prospective, non-interventional study will evaluate the efficacy and safety of Mircera in patients with stage III-IV chronic kidney disease (CKD) not on dialysis. Patients will receive open-label treatment with Mircera for 12 months at a dose to be determined by the investigator.

Inclusion Criteria:

• Patients with stage II-IV CKD not on dialysis, including renal transplant patients, who are receiving erythropoiesis-stimulating agent (ESA) treatment or are ESA-naive
• Patients who will not require dialysis within 12 months after the start of Mircera therapy
• Patients whose life expectancy is greater than 12 months after Mircera initiation
• Patients >/= 18 years and </= 75 years of age
• Patients who are female and of childbearing potential must be using effective contraception methods
• Patients with no contra-indications to ESA treatment (for example, hypersensitivity, non-controlled hypertension and others according to the local SmPC)
• Patients who have given written informed consent where local regulations allow or require it

Exclusion Criteria:

• Patients with stage I-II or stage V CKD
• Poorly controlled hypertension
• Active malignant disease